Loading company…
ID 405328863 · FY 2019–2024 · 6 years
კომპანიის ძირითადი საქმიანობაა საბიუმო ვაჭრობა ფარმაცევტული საქონლით, კომპანიას მინიჭებული აქვს სპეციალური სავაჭრო კომპანიის სტატუსი.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 25.2% | 24.4% | 18.7% | 9.5% | 19.8% | 21.1% |
| EBITDA Margin | 45.2% | 41.9% | 43.9% | 41.5% | 41.9% | 34.0% |
| EBITDAR | 8,228 | 5,894 | 3,519 | 3,508 | 2,230 | 5,555 |
| EBITDAR Margin | 45.2% | 41.9% | 43.9% | 41.5% | 41.9% | 34.0% |
| EBIT Margin | 45.2% | 41.6% | 43.3% | 41.0% | 41.4% | 33.9% |
| Net Profit Margin | 46.4% | 46.2% | 43.1% | 37.9% | 41.9% | 33.5% |
| Operating Expense % of Sales | 20.1% | 17.6% | 25.2% | 32.0% | 22.1% | 13.0% |
| Returns | ||||||
| Return on Assets (ROA) | 730.9% | 1482.3% | 303.7% | 133.4% | 957.5% | 253.9% |
| Return on Equity (ROE) | 910.3% | 2422.0% | 345.6% | 312.9% | 15402.6% | 685.3% |
| ROIC [EBIT / Invested Capital] | 2439.7% | 1624.8% | 428.8% | 363.2% | N/A | 2157.5% |
| Leverage & liquidity | ||||||
| Debt-to-Assets | 1.8% | 27.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.02x | 0.45x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.02x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 80.3% | 61.2% | 87.9% | 42.6% | 6.2% | 37.1% |
| Net Debt | -591 | 92 | -191 | -69 | -29 | -540 |
| Cash & Equivalents | 611 | 30 | 191 | 69 | 29 | 540 |
| Total Debt | 20 | 121 | N/A | N/A | N/A | N/A |
| Efficiency & working capital | ||||||
| Inventory Turnover | 26380.90x | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 0.0 | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 61.20x | N/A | 13.43x | 3.97x | 264.43x | 10.14x |
| Days Sales Outstanding (DSO) | 6.0 | N/A | 27.2 | 91.9 | 1.4 | 36.0 |
| Payables Turnover | 65.99x | 229.75x | 47.18x | 5.55x | 19.54x | 9.52x |
| Days Payable Outstanding (DPO) | 5.5 | 1.6 | 7.7 | 65.7 | 18.7 | 38.3 |
| Cash Conversion Cycle | 0.4 days | -1.6 days | 19.4 days | 26.2 days | -17.3 days | -2.3 days |
| Asset Turnover | 15.75x | 32.08x | 7.04x | 3.52x | 22.83x | 7.59x |
| Cash flow & dividends | ||||||
| Operating Cash Flow | 519 | -731 | 189 | -196 | -62 | 551 |
| Free Cash Flow (OCF − Capex proxy) | 519 | -937 | 178 | -134 | -62 | 551 |
| Cash Conversion (OCF / EBITDA) | 6.3% | -12.4% | 5.4% | -5.6% | -2.8% | 9.9% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).